| Leukemia, Myelomonocytic, Chronic
Iclusig vs Inqovi
Side-by-side clinical, coverage, and cost comparison for leukemia, myelomonocytic, chronic.Deep comparison between: Iclusig vs Inqovi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsInqovi has a higher rate of injection site reactions vs Iclusig based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Inqovi but not Iclusig, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Iclusig
Inqovi
At A Glance
Oral
Once daily
BCR::ABL kinase inhibitor
Oral
Once daily, Days 1-5 of each 28-day cycle
Nucleoside metabolic inhibitor
Indications
- Leukemia, Myelomonocytic, Chronic
- Philadelphia chromosome positive chronic myelogenous leukemia
- MYELODYSPLASTIC SYNDROME
- Refractory anemias
- Refractory anemia with ringed sideroblasts
- Refractory anaemia with excess blasts
- Leukemia, Myelomonocytic, Chronic
Dosing
Philadelphia chromosome positive chronic myelogenous leukemia 45 mg orally once daily; reduce to 15 mg once daily upon achievement of <=1% BCR::ABL IS.
AP-CML, BP-CML 45 mg orally once daily.
Newly diagnosed Ph+ ALL 30 mg orally once daily in combination with chemotherapy; reduce to 15 mg once daily upon achievement of MRD-negative CR at the end of induction.
Ph+ ALL (monotherapy, T315I-positive or no other KI indicated) 45 mg orally once daily.
MYELODYSPLASTIC SYNDROME, Refractory anemias, Refractory anemia with ringed sideroblasts, Refractory anaemia with excess blasts, Leukemia, Myelomonocytic, Chronic 1 tablet (35 mg decitabine and 100 mg cedazuridine) orally once daily on Days 1 through 5 of each 28-day cycle, taken on an empty stomach; minimum of 4 cycles until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>20%) Rash, arthralgia, abdominal pain, fatigue, headache, constipation, hypertension, dry skin, hepatotoxicity, fluid retention and edema, pyrexia, pancreatitis/lipase elevation, nausea, hemorrhage, anemia, arterial occlusive events, cardiac arrhythmias
Serious Arterial occlusive events, venous thromboembolic events, heart failure, hepatotoxicity, hypertension, pancreatitis, neuropathy, ocular toxicity, hemorrhage, fluid retention, cardiac arrhythmias, myelosuppression, tumor lysis syndrome, reversible posterior leukoencephalopathy syndrome, impaired wound healing, gastrointestinal perforation
Postmarketing Thrombotic microangiopathy, hyperthyroidism, gastrointestinal perforation, fistula, dehydration, reversible posterior leukoencephalopathy syndrome, severe cutaneous reactions (erythema multiforme, Stevens-Johnson syndrome), impaired wound healing, panniculitis, arterial aneurysms/dissections/rupture
Most common (>=20%) fatigue, constipation, hemorrhage, myalgia, mucositis, arthralgia, nausea, dyspnea, diarrhea, rash, dizziness, febrile neutropenia, edema, headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, transaminase increased
Serious febrile neutropenia, pneumonia, sepsis
Postmarketing differentiation syndrome, interstitial lung disease, cardiomyopathy
Pharmacology
Ponatinib is a kinase inhibitor that inhibits the tyrosine kinase activity of ABL and T315I mutant ABL, as well as VEGFR, PDGFR, FGFR, EPH receptor, and SRC family kinases, KIT, RET, TIE2, and FLT3, suppressing viability of cells expressing native or mutant BCR::ABL including T315I.
Decitabine is a nucleoside metabolic inhibitor that incorporates into DNA and inhibits DNA methyltransferase, causing hypomethylation and cellular differentiation or apoptosis; cedazuridine inhibits cytidine deaminase in the gastrointestinal tract and liver to increase systemic exposure of orally administered decitabine.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Iclusig
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Inqovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Iclusig
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Inqovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Iclusig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Inqovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Chronic Myeloid Leukemia (C.M.L.) - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Myelodysplastic Syndromes - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IclusigView full Iclusig profile
InqoviView full Inqovi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.